+123.1%
ASML vs MRNA
+463.0%
-339.9%
-22.0%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | +2.9% | -3.6% | +6.5% | +2.9% |
| 7D | +6.0% | -9.0% | +15.0% | +6.1% |
| 30D | +1.4% | +137.2% | -135.8% | -0.8% |
| 3M | +1.0% | +194.8% | -193.8% | -6.7% |
| 6M | +37.0% | +167.2% | -130.2% | +28.2% |
| YTD | +65.8% | +375.9% | -310.1% | +44.7% |
| 1Y | +123.1% | +465.2% | -342.1% | +89.8% |
| All | +123.1% | +463.0% | -339.9% | +89.8% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling